These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 2018836)
21. Fibrinogen Kiel: a congenital dysfibrinogenaemia with (A alpha-16 Arg----His) substitution characterized by HPLC without prior isolation of fibrinogen. Seydewitz HH; Gram J; Bruhn HD; Witt I Blood Coagul Fibrinolysis; 1991 Aug; 2(4):501-6. PubMed ID: 1768762 [TBL] [Abstract][Full Text] [Related]
22. B:b interactions are essential for polymerization of variant fibrinogens with impaired holes 'a'. Okumura N; Terasawa F; Haneishi A; Fujihara N; Hirota-Kawadobora M; Yamauchi K; Ota H; Lord ST J Thromb Haemost; 2007 Dec; 5(12):2352-9. PubMed ID: 17922804 [TBL] [Abstract][Full Text] [Related]
23. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin. Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959 [TBL] [Abstract][Full Text] [Related]
24. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis. Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000 [TBL] [Abstract][Full Text] [Related]
25. Characterization of fibrinogen Milano I: amino acid exchange gamma 330 Asp----Val impairs fibrin polymerization. Reber P; Furlan M; Rupp C; Kehl M; Henschen A; Mannucci PM; Beck EA Blood; 1986 Jun; 67(6):1751-6. PubMed ID: 3708159 [TBL] [Abstract][Full Text] [Related]
27. Fibrinogen Aarhus--a new case of dysfibrinogenemia. Hessel B; Stenbjerg S; Dyr J; Kudryk B; Therkildsen L; Blombäck B Thromb Res; 1986 Apr; 42(1):21-37. PubMed ID: 2939591 [TBL] [Abstract][Full Text] [Related]
28. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His). Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828 [TBL] [Abstract][Full Text] [Related]
29. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release. Lane DA; Cuddigan B; VanRoss M; Kakkar VV Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460 [TBL] [Abstract][Full Text] [Related]
30. [Functional analysis for dysfibrinogenemias, Toyama and Adachi, which have a mutation of Aalpha16Arg-->His (CGT-->CAT) with aberrant fibrinopeptide A release]. Soya K; Takezawa Y; Terasawa F; Okumura N Rinsho Byori; 2012 Jun; 60(6):499-505. PubMed ID: 22880226 [TBL] [Abstract][Full Text] [Related]
31. Fibrinogen Milano XII: a dysfunctional variant containing 2 amino acid substitutions, Aalpha R16C and gamma G165R. Bolliger-Stucki B; Lord ST; Furlan M Blood; 2001 Jul; 98(2):351-7. PubMed ID: 11435303 [TBL] [Abstract][Full Text] [Related]
32. Fibrinogen Geneva, a new case of A alpha 16 Arg----Cys dysfibrinogenaemia. Furlan M; Bögli C; Hofer A; Bouvier CA; de Moerloose P Blood Coagul Fibrinolysis; 1990 Jun; 1(2):139-43. PubMed ID: 2130925 [TBL] [Abstract][Full Text] [Related]
33. Functional analysis of recombinant Bbeta15C and Bbeta15A fibrinogens demonstrates that Bbeta15G residue plays important roles in FPB release and in lateral aggregation of protofibrils. Hirota-Kawadobora M; Kani S; Terasawa F; Fujihara N; Yamauchi K; Tozuka M; Okumura N J Thromb Haemost; 2005 May; 3(5):983-90. PubMed ID: 15869595 [TBL] [Abstract][Full Text] [Related]
34. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B. Branson HE; Schmer G; Theodor I; Pirkle H Acta Haematol; 1983; 70(4):257-63. PubMed ID: 6414212 [TBL] [Abstract][Full Text] [Related]
35. The impact of delayed fibrinopeptide-A release on fibrin structure. Studies of an abnormal fibrinogen. Carr ME; Qureshi GD J Biol Chem; 1987 Nov; 262(32):15568-74. PubMed ID: 3680212 [TBL] [Abstract][Full Text] [Related]
36. Fibrinogen Manchester: identification of an abnormal fibrinopeptide A with a C-terminal arginine leads to histidine substitution. Southan C; Kehl M; Henschen A; Lane DA Br J Haematol; 1983 May; 54(1):143-51. PubMed ID: 6849832 [TBL] [Abstract][Full Text] [Related]
37. Fibrinogen Alès: a homozygous case of dysfibrinogenemia (gamma-Asp(330)-->Val) characterized by a defective fibrin polymerization site "a". Lounes KC; Soria C; Mirshahi SS; Desvignes P; Mirshahi M; Bertrand O; Bonnet P; Koopman J; Soria J Blood; 2000 Nov; 96(10):3473-9. PubMed ID: 11071644 [TBL] [Abstract][Full Text] [Related]
38. Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality. Andes WA; Chavin SI; Beltran G; Stuckey WJ Thromb Res; 1982 Jan 1-15; 25(1-2):41-50. PubMed ID: 6801812 [TBL] [Abstract][Full Text] [Related]
39. Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach. Henschen A; Kehl M; Deutsch E Hoppe Seylers Z Physiol Chem; 1983 Dec; 364(12):1747-51. PubMed ID: 6667926 [TBL] [Abstract][Full Text] [Related]
40. Fibrinogen Mitaka II: a hereditary dysfibrinogen with defective thrombin binding caused by an A alpha Glu-11 to Gly substitution. Niwa K; Yaginuma A; Nakanishi M; Wada Y; Sugo T; Asakura S; Watanabe N; Matsuda M Blood; 1993 Dec; 82(12):3658-63. PubMed ID: 7903170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]